Ferric carboxymaltose prevents recurrence of anemia in patients with inflammatory bowel disease

Rayko Evstatiev, Olga Alexeeva, Bernd Bokemeyer, Ivan Chopey, Marcel Felder, Maja Gudehus, Tariq Iqbal, Igor Khalif, Philippe Marteau, Jürgen Stein, Christoph Gasche, FERGI Study Group, Vibeke Andersen

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Abstrakt

Iron-deficiency anemia is the most common systemic complication of inflammatory bowel diseases (IBD). Iron-deficiency anemia recurs frequently and rapidly after iron-replacement therapy in patients with IBD. We performed a randomized, placebo-controlled trial to determine if administration of ferric carboxymaltose (FCM) prevents anemia in patients with IBD and low levels of serum ferritin.

Fingeraftryk

Dyk ned i forskningsemnerne om 'Ferric carboxymaltose prevents recurrence of anemia in patients with inflammatory bowel disease'. Sammen danner de et unikt fingeraftryk.

Citationsformater